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ABSTRACT
Aims/Introduction: We investigated the association between four insulin regimens,
and increase in glycated hemoglobin (HbA1c) and insulin dose in a real-life clinical setting
because there are no data about them among insulin regimens.
Materials and Methods: Participants included 757 patients with type 2 diabetes hav-
ing been treated with insulin therapy for more than 1 year. The four insulin regimens
were regimen 1 (long-acting insulin, once daily), regimen 2 (biphasic insulin, twice daily),
regimen 3 (biphasic insulin, three times daily) and regimen 4 (basal–bolus therapy). Main
outcomes were increases in HbA1c levels >0.5% and increases in daily insulin units after
1 year. We carried out multivariable analyses to examine differences in glycemic control
and insulin dose with adjustment for possible confounders.
Results: Mean HbA1c level and duration of insulin therapy were 7.8% and 11.3 years,
respectively. HbA1c levels increased by >0.5% at follow up in 22.8, 24.9, 20.7, and 29.3% of
participants using regimen 1, 2, 3 and 4, respectively, with no significant differences
between groups. Daily insulin doses increased in 62.3, 68.8, 65.3 and 38.6% of patients,
respectively (P < 0.001). Multivariable regression analysis showed that patients who
received regimen 4 had significantly lower odds of requiring future insulin dose increases
than those who had received regimen 2 (adjusted odds ratio 0.24, 95% confidence inter-
val 0.14–0.41; P < 0.001).
Conclusions: Many patients receiving insulin therapy showed increases in HbA1c levels
and insulin doses 1 year later. The smallest increase in insulin dose was observed in the
basal–bolus therapy group compared with other regimens.
INTRODUCTION
The number of patients with type 2 diabetes is increasing
worldwide. In 2015, it was estimated that 415 million people
had diabetes, 5.0 million people died from complications of dia-
betes and up to $1,197 billion were spent as a result of diabetes
worldwide1. In high-income countries, type 2 diabetes accounts
for >90% of cases of diabetes1. The main cause of death in
patients with type 2 diabetes is cardiovascular disease, but other
complications including diabetic nephropathy, retinopathy, and
neuropathy can also shorten patients’ lives and lower patients’
quality of life1–4. The United Kingdom Prospective Diabetes
Survey showed that tight glycemic control could decreaseReceived 18 December 2016; revised 5 April 2017; accepted 7 May 2017
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diabetic complications compared with conventional glycemic
control5,6. Glycemic control is as important as blood pressure
and lipid control to prevent the occurrence and progression of
diabetic complications in patients with type 2 diabetes7. Gaede
et al.8 reported that compared with conventional treatment,
intensive integrated therapy for hyperglycemia, dyslipidemia
and hypertension was effective to reduce cardiovascular events,
as well as nephropathy, retinopathy and autonomic neuropathy
in approximately half of patients.
In general, when optimal glycemic control is not obtained
with dietary therapy and exercise, one or more oral antidiabetic
drugs (OADs) is added to the treatment regimen. If sufﬁcient
glycemic control is not reached with OADs, insulin therapy is
introduced. Recently, glucagon-like peptide-1 receptor agonists
have become available as another glucose-lowering agent; these
agents can also be combined with OADs. As with OADs alone,
when optimal glycemic control is not obtained with glucagon-
like peptide-1 receptor agonists and OADs, induction of insulin
therapy is recommended9,10.
Many insulin formulations are available, and a variety of
insulin regimens have been proposed9–11. Randomized con-
trolled trials suggest an association between a higher frequency
of daily insulin injections and greater glycemic improvement in
insulin-na€ıve patients with type 2 diabetes12,13. However, a
higher frequency of daily insulin injections is also associated
with a higher occurrence of hypoglycemia12,13.
Previous trials observed changes in glycemic control shortly
after insulin initiation. It is not clear whether there is a differ-
ence in glycemic control among the variety of insulin regimens
after their introduction in real-life clinical settings. Thus far, no
observational studies have examined practice patterns of glyce-
mic control in patients with type 2 diabetes who have been
undergoing insulin therapy for long periods.
Here, we analyzed data of a cohort of Japanese patients with
diabetes from a large-scale single-center registry to investigate
the association between different methods of insulin therapy in
real-life clinical settings and subsequent changes in glycemic
control in patients with type 2 diabetes. We also examined
factors associated with better glycemic control.
METHODS
Participants
Patient data were derived from the second-year survey of a dia-
betes registry at Tenri Hospital, Tenri City, Nara, Japan, a
regional tertiary-care teaching hospital. Details of this registry
can be found elsewhere14–21. In brief, Diabetes Distress and
Care Registry at Tenri is a cohort study evaluating the cross-
sectional and prospective association among psychosocioeco-
nomic factors, biomedical markers, therapy and complications
in patients with diabetes in real-life clinical settings. The registry
recruited patients diagnosed with diabetes who had visited the
outpatient clinic of our hospital between October 2009 and
December 2011. We excluded patients with prediabetes diag-
nosed by an oral glucose tolerance test, gestational diabetes,
type 1 diabetes, or diabetes induced by steroid use or other
endocrinological diseases. We used data only from patients with
type 2 diabetes. At registration, the attending physician con-
ﬁrmed the diagnosis according to the Classiﬁcation and Diag-
nostic Criteria of Diabetes Mellitus by the Japan Diabetes
Society22. For the current analysis, we included patients who
had been undergoing insulin therapy with any of the four regi-
mens described later for more than 1 year. Exclusion criteria
were renal dysfunction (estimated glomerular ﬁltration rate
<15 mL/min/1.73 m2), because it could interfere with the rela-
tionship between blood glucose levels and glycated hemoglobin
(HbA1c)23. Patients who started insulin therapy within 1 year
were also excluded, because signiﬁcant changes in HbA1c levels
are known to occur within the ﬁrst year of insulin initia-
tion12,13. Written informed consent was collected from patients.
The Ethics Committee of Kyoto University and Tenri Hospital
approved this study.
Data collection
On the survey date, patients underwent routine medical history
inquiries, physical examinations and laboratory tests. Clinical
research coordinators collected the patients’ demographics, such
as age, sex, bodyweight, height, duration of diabetes and treat-
ment modalities, from their medical charts. With regard to
patients undergoing insulin therapy, duration from insulin initi-
ation, daily insulin dose and frequency of self-monitoring of
blood glucose were also collected. We assessed patient-reported
adherence to scheduled insulin regimens using the response to
the following questionnaire: ‘How often did you omit insulin
injections in the past month?’ (response options: 1, never; 2,
seldom; 3, less than half of the time; 4, more than half of the
time; 5, usually; and 6, always).
Insulin regimens
Main exposures in the present study were one of four insulin
regimens: regimen 1 (insulin glargine, once daily), regimen 2
(biphasic insulin, twice daily), regimen 3 (biphasic insulin, three
times daily) and regimen 4 (rapid-acting insulin analog, three
times daily; and long-acting insulin, once daily), based on the
frequency of insulin injection9–11. These speciﬁc regimens
included the largest number of patients among those receiving
one to four insulin injections daily. The rapid-acting insulin
analog used was insulin aspart (Novo Rapid; Novo Nordisk,
Bagsværd, Denmark) or insulin lispro (Humalog; Eli Lilly,
Indianapolis, IN, USA) in the present study. Long-acting insu-
lin included neutral protamine Hagedorn (Novolin N; Novo
Nordisk), insulin neutral protamine lispro (Humalog N; Eli
Lilly), insulin detemir (Levemir; Novo Nordisk) or insulin
glargine (Lantus; Sanoﬁ-Aventis, Paris, France). Biphasic insu-
lin included lispro mix 75/25 (75% insulin lispro protamine
suspension and 25% of insulin lispro; Eli Lilly), lispro mix 50/
50 (50% insulin lispro protamine suspension and 50% of insu-
lin lispro; Eli Lilly) or aspart 30/70 mix (70% protamine-crystal-
lized aspart and 30% soluble insulin aspart; Novo Nordisk).
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Outcome measures
The main outcomes were: (i) increase in HbA1c level >0.5% in
1 year; (ii) increase in insulin dose 1 year later; (iii) addition of
OADs in 1 year; and (iv) weight gain in 1 year. HbA1c levels,
total daily insulin doses, doses of concomitant OADs, body-
weight, and BMI were evaluated at baseline and 12 months
after registration in the cohort study. Increases in insulin dose
were assessed because these increases are thought to be as
important as glycemic control itself, as increasing insulin doses
are associated with weight gain and diabetes-related distress24.
Excessive weight gain has a harmful effect on lipid levels and
blood pressure25, and diabetes-related distress disturbs glycemic
control26.
We also evaluated adverse events within 90 days of baseline,
such as frequency of hypoglycemia, experience of severe hypo-
glycemia and frequency of severe hypoglycemia, according to
insulin regimen. Hypoglycemia was deﬁned as a case in which
a patient felt hypoglycemic symptoms or a case in which mea-
sured blood glucose levels were ≤50 mg/dL, even if a patient
did not feel hypoglycemic symptoms. Severe hypoglycemia was
deﬁned as a case in which a patient lost consciousness or a case
in which other people’s help was required to recover from
hypoglycemia.
Statistical analysis
We categorized patients according to insulin regimens. We
compared data among the four insulin regimens regarding out-
comes; that is: (i) increase in HbA1c level >0.5% in 1 year; (ii)
increase in insulin dose in 1 year later; (iii) addition of OADs
in 1 year; and (iv) weight gain in 1 year. Continuous variables
are reported as mean – standard deviations (SD), and nominal
variables are reported as proportions (%). We used analysis of
variance to compare continuous variables among the insulin
regimens. We also carried out Fisher’s exact test for nominal
variables.
Then, we used logistic regression analysis to estimate the odds
ratios (OR) and 95% conﬁdence intervals (CI) of outcomes (i)
and (ii), adjusted for possible confounding factors including age,
sex, baseline HbA1c level, duration of diabetes, duration
from insulin initiation, presence of OAD use and adherence to
insulin therapy. We categorized duration of diabetes into
four groups: (i) <10 years; (ii) 10–15 years; (iii) 15–20 years;
and (iv) ≥20 years. We categorized adherence to insulin therapy
into two groups: those who had no experience forgetting an
insulin injection (1 = never), and those who had experience
forgetting insulin injections (2 = seldom to 6 = always), in
order to decrease the deviation in the number of patients. We
set regimen 2 as the reference group to make the model most
stable, because the largest number of patients were in this
group. Also, we carried out sensitivity analysis with an aim to
assess the robustness of the primary outcome (i): increase in
HbA1c level >0.5% in 1 year. We changed the cut-off level of
an increase of HbA1c >0.5 to 0.1, 0.2, 0.3 and 0.4% in these
analyses. For univariate analyses, we used Fisher’s exact test for
categorized variables and analysis of variance test for continuous
variables. All analyses were carried out using the Stata/SE
version11.2 (StataCorp LP, College Station, Texas, USA).
P < 0.05 was considered statistically signiﬁcant.
RESULTS
At baseline, 3,717 patients with type 2 diabetes were registered.
Of these 3,717 patients, 1,191 patients (32.0%) without renal
dysfunction had been undergoing insulin therapy for more than
1 year. Of these 1,191 patients, 434 patients were excluded
because of undergoing insulin therapy with other regimens.
Seven hundred and ﬁfty-seven patients with type 2 diabetes
were included in the ﬁnal analysis (Figure 1). Baseline charac-
teristics of patients are shown in Table 1. The mean age was
65.7 years (SD 10.7) and mean HbA1c level was 7.8% (SD 1.2).
The mean duration from insulin initiation was 11.3 years (SD
7.7). There were no statistical differences among different insu-
lins within each treatment group (e.g., lispro mix 75/25, lispro
mix 50/50 and aspart 30/70 mix in regimen 2).
At baseline, HbA1c level ≤6.9% was seen in 26.6, 23.9, 20.4,
and 22.9% of patients treated with regimen 1, 2, 3 and 4,
respectively. At the end of follow up, HbA1c level ≤6.9% was
achieved in 27.8, 23.3, 23.4, and 26.8% of patients with regimen
1, 2, 3 and 4, respectively, with no signiﬁcant differences
between groups (P = 0.76). The percentage of participants
using concomitant OADs was highest in regimen 1 and was
lowest in regimen 4. There was no signiﬁcant association
between severe hypoglycemia and insulin regimens in either
number of hypoglycemic episodes or the percentage of patients
experiencing these episodes (P = 0.39 and 0.24, respectively).
There was a signiﬁcant difference in hypoglycemia among the
four insulin regimens (P = 0.005).
In regimen 4, 14 patients were prescribed neutral protamine
Hagedorn, and 69 patients were prescribed insulin analogs (1
insulin neutral protamine lispro, 13 insulin detemir and 54
insulin glargine). There was no signiﬁcant difference in hypo-
glycemia between the two groups (P = 0.30). The number of
severe hypoglycemic episodes or the percentage of patients
experiencing these episodes were smaller in patients prescribed
insulin analogs (0.071 vs 0.043 times per 90 person days and
7.1 vs 2.9%, respectively), but not signiﬁcant.
Main outcomes
The percentage of patients whose HbA1c level increased >0.5%
after 1 year were 22.8, 24.9, 20.7, and 29.3% with regimen 1, 2,
3 and 4, respectively, with no signiﬁcant differences between
groups (Table 2). In contrast, daily insulin doses were increased
1 year later in 62.3, 68.8, 65.3, and 38.6% of patients receiving
regimen 1, 2, 3 and 4, respectively (P < 0.001), whereas no sig-
niﬁcant differences were observed among regimens in OAD
use (P = 0.37). Added OADs including classiﬁcation and dose
of medication are shown in Table S1. Weight gain was
observed only in regimen 2 (P = 0.03). In regimen 4, patients
prescribed neutral protamine Hagedorn signiﬁcantly increased
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Patients with Type 2 diabetes
undergoing insulin therapy
n = 1,368
177 patients were excluded
434 patients were excluded
Insulin initiation within 1 year (n = 126)
Biphasic or short-acting insulin, once daily (n = 71)
Long-acting insulin, twice daily (n = 50)
Short-acting insulin, three times daily (n = 79)
Combination of Short-acting and biphasic insulin (n = 51)
Other regimes (n = 183)
Renal dysfunction (n = 51)






Figure 1 | Selection process for the study population.












Male (%) 56.1 53.2 55.8 57.8 57.8 0.90
Age (years) 65.7 (10.7) 64.0 (11.8) 67.1 (10.2) 65.4 (8.8) 59.9 (12.7) <0.001
HbA1c (%) 7.8 (1.2) 7.9 (1.4) 7.8 (1.1) 8.0 (1.2) 7.8 (1.4) 0.17
HbA1c ≤6.9% (%) 23.4 26.6 23.9 20.4 22.9 0.74
Duration of diabetes (years) 17.9 (9.8) 13.4 (10.0) 18.4 (9.8) 18.2 (9.4) 18.4 (9.7) <0.001
Duration from insulin initiation (year) 11.3 (7.7) 11.0 (9.7) 11.2 (7.2) 12.4 (8.1) 10.6 (7.7) 0.38
Daily insulin dose (unit/kg) 0.43 (0.25) 0.18 (0.09) 0.40 (0.20) 0.49 (0.23) 0.68 (0.34) <0.001
OAD use (%) 45.3 79.7 45.8 42.2 15.7 <0.001
BMI (kg/m2) 24.8 (3.8) 24.6 (3.7) 24.8 (3.6) 24.9 (3.9) 25.2 (4.6) 0.62
SMBG (times/day) 1.8 (1.0) 1.2 (0.8) 1.7 (0.9) 2.3 (1.0) 2.2 (1.3) <0.001
Perfect adherence to insulin therapy (%) 69.9 70.1 71.5 64.6 69.9 0.47
Hypoglycemia (times/90 person days) 2.0 (4.1) 0.4 (1.2) 2.1 (4.5) 2.2 (3.7) 2.4 (4.2) 0.005
Severe hypoglycemia (times/90 person days) 0.021 (0.18) 0 (0.0) 0.024 (0.19) 0.007 (0.08) 0.048 (0.27) 0.39
Severe hypoglycemia (%) 1.86 0 2.24 0.68 3.61 0.24
Data presented as percentage for nominal variables, and mean (standard deviation) for continuous variables. BMI, body mass index; HbA1c, glycated
hemoglobin; OAD, oral antidiabetic drug; Regimen 1, long-acting (once daily); Regimen 2, biphasic (twice daily); Regimen 3, biphasic (three times
daily); Regimen 4, rapid-acting (three times daily) + long-acting (once daily); SMBG, self-monitoring of blood glucose.
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bodyweight compared with those prescribed insulin analogs
(+1.2 kg vs -1.0 kg, P = 0.035).
Multivariable regression analysis showed that there were no
statistically signiﬁcant differences among insulin regimens in
increase in HbA1c level >0.5% after 1 year (Table 3). Age (ad-
justed OR [AOR] 0.76, 95% CI: 0.63–0.91) and higher HbA1c
level at baseline (AOR 0.68, 95% CI: 0.57–0.80) were signiﬁ-
cantly associated with HbA1c exacerbation at the end of follow
up. With regard to the relationship between insulin regimens
and increase in insulin doses at the end of follow up, multivari-
able analysis showed that patients who received regimen 4
(AOR 0.24, 95% CI: 0.14–0.41) had signiﬁcantly lower odds of
increasing daily insulin units 1 year later compared with
patients who received regimen 2 (Table 4).
Sensitivity analysis
We carried out sensitivity analysis changing the cut-off level of
an increase of HbA1c 1 year later to a 0.1, 0.2, 0.3 or 0.4%.
There were no signiﬁcant differences among insulin regimens
in hyperglycemic exacerbations with any cut-off level used
(Table 5).
DISCUSSION
The goal of treatment in patients with diabetes is to prevent
diabetic complications to extend life expectancy and maintain
quality of life. As several longitudinal studies suggest, glycemic
control is one of the most important factors in the prevention
of diabetic complications5–7. In clinical practice, however,
patients and clinicians know the difﬁculty of maintaining glyce-
mic control27. In the present study, we examined which insulin
regimen was better at maintaining glycemic control and not
increasing daily insulin doses for patients with type 2 diabetes
over an extended period. All four regimens had the same
impact on glycemic control, but an increase in insulin dose was
less likely in regimen 4 compared with other regimens. In regi-
men 4, patients prescribed neutral protamine Hagedorn










HbA1c exacerbation >0.5% (%) 22.8 24.9 20.7 29.3 0.51
Increase in insulin doses (%) 62.3 68.8 65.3 38.6 <0.001
Addition of OAD (%) 30.4 27.7 27.2 19.3 0.37
Weight gain (kg) –0.29 0.51 –0.23 –0.67 0.03
Data are presented as number (%). P-values were determined by Fisher’s exact tests for categorized variables and by analysis of variance test for
continuous variables. OAD, oral antidiabetic drug; Regimen 1, long-acting (once daily); Regimen 2, biphasic (twice daily); Regimen 3, biphasic (three
times daily); Regimen 4, rapid-acting (three times daily) + long-acting (once daily).
Table 3 | Factors associated with glycated hemoglobin exacerbations >0.5% in multivariable analysis
Adjusted OR 95% CI P-value
Insulin regimen
Regimen 1 0.88 (0.48–0.61) 0.68
Regimen 2 Reference – –
Regimen 3 0.82 (0.51–1.31) 0.40
Regimen 4 1.05 (0.59–1.87) 0.86
Age (per 10-year increase) 0.76 (0.63–0.91) 0.003
Male (vs female) 0.75 (0.52–1.06) 0.10
Duration of diabetes
<10 years Reference – –
10–15 years 0.92 (0.55–1.52) 0.74
15–20 years 1.25 (0.76–2.05) 0.39
>20 years 1.63 (1.02–2.60) 0.04
HbA1c at baseline (per 1% increase) 0.68 (0.57–0.80) <0.001
OAD use (vs no use) 1.10 (0.76–1.60) 0.60
Poor adherence (vs good adherence) 1.33 (0.91–1.94) 0.14
For adjusted adds ratio (OR), confounding factors comprised of age, sex, baseline glycated hemoglobin (HbA1c) levels, duration of diabetes, dura-
tion from insulin initiation, presence of oral antidiabetic drug (OAD) use and adherence to insulin therapy were involved. CI, confidence interval;
Regimen 1, long-acting (once daily); Regimen 2, biphasic (twice daily); Regimen 3, biphasic (three times daily); Regimen 4, rapid-acting (three times
daily) + long-acting (once daily).
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signiﬁcantly increased bodyweight and tended to experience
severe hypoglycemic events compared with those prescribed
insulin analogs, which is compatible with another study28.
The present study showed that mean HbA1c levels were
approximately 7.8% in all four insulin regimens. In most
patients, HbA1c levels were above recommended standards
(≤6.9%). A target HbA1c level ≤6.9% was achieved in just 20–
30% of patients in each regimen, although patients continued
their insulin therapies for more than 10 years on average.
Kobayashi et al.29 reported mean HbA1c levels of Japanese
patients with type 2 diabetes undergoing insulin therapy was
8.3%, which is even higher than the results in the present
study. In the Steno 2 study, HbA1c level <6.5% was achieved
in just 15% of patients assigned to intensive therapy8. These
again showed how difﬁcult it is to attain good glycemic control.
In addition, HbA1c levels increased by >0.5% in >20% of
patients in all the four insulin regimens, even though these
patients were treated in a clinic specializing in diabetes and
insulin therapy.
It appears that optimal glycemic control cannot always be
obtained even when insulin, the most powerful glucose-lower-
ing agent, is used. This ﬁnding could be due to the fact that
lifestyle factors, such as diet and exercise, might change with
the introduction of insulin. It is also possible that good glyce-
mic control cannot be maintained because of fears of hypo-
glycemia, as we know simple increasing of insulin dose for
poor controlled patients can cause severe hypoglycemia and
cardiovascular complication30. As a result, the insulin prescrip-
tion could be inappropriate to control it despite patients having
increased their HbA1c levels during the follow-up period.
When increasing HbA1c levels are seen in patients with dia-
betes, doctors add OADs or increase insulin doses, as well as
reconﬁrm diet and exercise therapy. In the present study,
OADs were added for 20–30% of patients, and insulin doses
were increased for 35–70% of patients after 1 year. The insulin
dose 1 year later was less likely to increase in regimen 4 com-
pared with the other regimens. In contrast, the occurrence of
hypoglycemia was highest with regimen 4 and lowest with
Table 4 | Factors associated with increase in insulin doses in multivariable analysis
Adjusted OR 95% CI P-value
Insulin regimen
Regimen 1 0.78 (0.46–1.31) 0.34
Regimen 2 Reference – –
Regimen 3 0.84 (0.56–1.26) 0.40
Regimen 4 0.24 (0.14–0.41) <0.001
Age (per 10-year increase) 0.84 (0.71–0.99) 0.04
Male (vs female) 0.97 (0.71–1.33) 0.87
Duration of diabetes
<10 years Reference – –
10–15 years 0.57 (0.37–0.88) 0.01
15–20 years 0.78 (0.50–1.22) 0.28
>20 years 0.97 (0.63–1.50) 0.89
HbA1c at baseline (per 1% increase) 1.04 (0.91–1.20) 0.54
OAD use (vs no use) 0.96 (0.69–1.34) 0.81
Poor adherence (vs good adherence) 0.96 (0.68–1.34) 0.80
For adjusted odds ratio (OR), confounding factors comprised of age, sex, baseline glycated hemoglobin (HbA1c) levels, duration of diabetes, dura-
tion from insulin initiation, presence of oral antidiabetic drug (OAD) use and adherence to insulin therapy were involved. CI, confidence interval;
Regimen 1, long-acting (once daily); Regimen 2, biphasic (twice daily); Regimen 3, biphasic (three times daily); Regimen 4, rapid-acting (three times
daily) + long-acting (once daily).










Increase of HbA1c level
>0.4% (%) 30.4 31.7 26.9 40.2 0.23
>0.3% (%) 34.2 35.5 33.1 43.9 0.41
>0.2% (%) 40.5 38.9 37.2 47.6 0.46
>0.1% (%) 41.8 42.8 43.6 48.8 0.77
HbA1c, glycated hemoglobin; Regimen 1, long-acting (once daily); Regimen 2, biphasic (twice daily); Regimen 3, biphasic (three times daily);
Regimen 4, rapid-acting (three times daily) + long-acting (once daily).
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regimen 1. As the frequency of daily injections increased, the
occurrence of hypoglycemia also increased, supporting previous
studies12,13. We should pay attention to hypoglycemia, because
there is a strong association between hypoglycemia and vascular
events or decreased quality of life31–33. Although there was a
signiﬁcant difference in hypoglycemia among the four regimens,
the occurrence was less than once a month in all regimens,
which might be considered clinically acceptable.
We carried out multivariable logistic regression analysis with
adjustment for possible confounders. There was no signiﬁcant
difference in the change in HbA1c levels of each regimen com-
pared with regimen 2. In the present study, consistent with
another report34, younger patients tended to show worse
HbA1c levels compared with elderly patients. In the present
study, patients with higher HbA1c at baseline were less likely
to show worse HbA1c levels after 1 year. This result might be
explained by the fact that a patient with better glycemic control
at baseline (e.g., HbA1c ≤6.0%) remained at fair glycemic con-
trol even if HbA1c increased by >0.5%, and the physician
might have decided not to add more intervention, because
HbA1c levels were still within the target. With regard to the
increase in insulin dose, multivariable analysis showed that
patients receiving regimen 4 had signiﬁcantly lower odds of
receiving increased insulin doses than patients receiving regi-
men 2. Insulin doses were unlikely to be increased as a patient
aged, which might reﬂect the fact that doctors hesitated to
increase insulin doses in older patients due to fears of hypo-
glycemia. We changed the cut-off level of an increase in HbA1c
>0.5%. Results of sensitivity analysis were also satisfactory after
redeﬁning the cut-off level of HbA1c elevation.
There were several limitations to this study. The generaliz-
ability of these results is limited, because data are from a sin-
gle-center, observational study. We adjusted confounding
factors in the multivariable analysis, but there remain possibili-
ties that we could not adjust all the confounders including
those we did not measure (degree of motivation and adherence
to diet and exercise therapy, endogenous insulin secretion, and
frequency of educational intervention by medical staff) and
other unknown confounders. Furthermore, we cannot exclude
the inﬂuence of indication bias, because the insulin regimens
prescribed to the patients in the present study were based on
clinical decisions.
The present study was based on real-world data of 757
patients with type 2 diabetes undergoing insulin therapy for
more than 1 year who were treated at an outpatient clinic spe-
cializing in diabetes. Regardless of the insulin regimen used, a
considerable number of patients treated with insulin therapy
showed increases in both HbA1c levels and insulin doses at the
end of follow up. These ﬁndings indicate the limitations and
unmet needs of current insulin regimens. Multivariable regres-
sion analysis showed that patients who received regimen 4 had
the smallest odds of requiring future insulin dose increases.
This might be because a basal–bolus therapy has the largest
number of injections, which enables precise and subtle
adjustment of insulin doses supported by and based on results
of self-monitoring of blood glucose, with eventually little
increase in total daily doses. The current study provides insights
on real-life clinical scenarios, and reminds us of the importance
of basal–bolus therapy.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article:
Table S1 | Classiﬁcation and dose of added OADs.
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